top of page
What's the Latest
New Case Study Highlights the Risk of Severe Treatment Delays for U.S. Patients Fighting Cancer Due to MFN
For millions of Americans living with cancer, access to innovative treatments is urgent and often lifesaving. The U.S. has long led the world in developing cutting-edge therapies, giving patients earlier access to new medicines and contributing to improved survival rates and quality of life. With 345 cancer medicines launched over a twelve-year span compared to just 191 in the U.K., a difference that translates directly into more treatment options and better outcomes for pati
7 days ago
New Analysis: Patients Paid the Price When Europe Controlled Drug Costs
Patients lose access to lifesaving therapies when governments impose drug price controls, and the consequences are measured in delayed treatment, depleted research pipelines and lives cut short, according to a new research analysis from the Information Technology and Innovation Foundation (ITIF). ITIF examined how European drug pricing policies drove the continent's fall from global biopharmaceutical leadership. While compiling and assessing existing research on the patient i
Mar 18
Lowering Health Care Costs and Improving Overall Outcomes Cannot Come at a Cost to Patient Access
February 25, 2026 (WASHINGTON, D.C.) — The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the State of the Union address, during which President Trump supported codifying “Most Favored Nation” (MFN) drug pricing: “The 194 million Americans living with multiple chronic conditions depend on consistent, timely access to the therapies that help manage their health. Ensuring these treatments are affordable is a goal PFCD strongly suppo
Feb 25
PFCD Celebrates Passage of PBM Reforms Critical to Lowering Costs and Improving Outcomes for Americans with Chronic Disease
February 4, 2026 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) applauds the passage of the Consolidated Appropriations Act of 2026 and its inclusion of many important health care elements that support efforts to better prevent and manage costly chronic conditions. Notably, the bill will increase transparency and lower health care costs for people living with one or more chronic conditions by instituting much needed reforms for pharmacy benefit managers (
Feb 4
Medicare Drug Pricing Must Not Create New Barriers for People Living with Chronic Disease
January 28, 2026 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare & Medicaid Services (CMS) announcement of 15 new drugs selected for price-setting in Initial Price Applicability Year (IPAY) 2028: “Prescription medicines are a cornerstone of chronic disease management for Medicare beneficiaries, the vast majority of whom rely on one or more medications every month to maintain their hea
Jan 28
Chronic Disease is Straining U.S. Health Care, and Insurers Aren’t Helping
Chronic conditions are the primary driver of rising U.S. health care spending across Medicare, Medicaid and private insurance, a new study from the Partnership to Fight Chronic Disease (PFCD) detailed last week. Costs are highly concentrated among patients living with three or more chronic conditions, and obesity plays a central role . PFCD Chair Kenneth Thorpe, PhD., and Peter Joski authored the new research report , which is particularly relevant leading up to two House hea
Jan 21
bottom of page